Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions

被引:53
作者
Shukla, Ajay K. [1 ]
Jhaj, Ratinder [1 ]
Misra, Saurav [1 ]
Ahmed, Shah N. [2 ]
Nanda, Malaya [1 ]
Chaudhary, Deepa [3 ]
机构
[1] AIIMS Bhopal, Dept Pharmacol, Bhopal, Madhya Pradesh, India
[2] Coll Med & JNM Hosp, Dept Pharmacol, Kalyani, W Bengal, India
[3] AIIMS Bhopal, Dept ADR Monitoring Ctr AMC, Bhopal, Madhya Pradesh, India
关键词
Agreement between scales; causality assessment; Naranjo algorithm; WHO-UMC scale; PROBABILITY; CRITERIA; EVENTS;
D O I
10.4103/jfmpc.jfmpc_831_21
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The Pharmacovigilance Program of India recommends the use of the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) scale, while many clinicians prefer the Naranjo algorithm for its simplicity. In the present study, we assessed agreement between the two widely used causality assessment scales, that is, the WHO-UMC criteria and the Naranjo algorithm. Materials and Methods: In this study, 842 individual case safety reports were randomly selected from 1000 spontaneously reported forms submitted to the ADR Monitoring Center at a tertiary healthcare Institute in Central India between 2016 and 2018. Two well-trained independent groups performed the causality assessment. One group performed a causality assessment of the 842 ADRs using the WHO-UMC criteria and the other group performed the same using the Naranjo algorithm. The agreement between two ADR causality scales was assessed using the weighted kappa (kappa) test. Results: Cohen's kappa coefficient (kappa) statistical test was applied between the two scales (WHO-UMC scale and Naranjo algorithm) to find out the agreement between these two scales. "No" agreement was found between the two scales {Kappa statistic with 95% confidence interval = 0.048 (P < 0.001)}. Conclusion: There was no agreement found between the WHO-UMC criteria and the Naranjo algorithm in our study.
引用
收藏
页码:3303 / 3308
页数:6
相关论文
共 22 条
  • [1] Acharya T. A., 2020, BIOMED PHARMACOL J, V13, P79, DOI [10.13005/bpj/1863, DOI 10.13005/bpj/1863]
  • [2] Methods for causality assessment of adverse drug reactions - A systematic review
    Agbabiaka, Taofikat B.
    Savovic, Jelena
    Ernst, Edzard
    [J]. DRUG SAFETY, 2008, 31 (01) : 21 - 37
  • [3] Factors affecting the development of adverse drug reactions (Review article)
    Alomar, Muaed Jamal
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2014, 22 (02) : 83 - 94
  • [4] [Anonymous], 2012, LIVERTOX CLIN RES IN
  • [5] [Anonymous], 2002, Safety of Medicines: A Guide to Detecting and Reporting Adverse Drug Reactions
  • [6] Comparison of different methods for causality assessment of adverse drug reactions
    Behera, Sapan Kumar
    Das, Saibal
    Xavier, Alphienes Stanley
    Velupula, Srinivas
    Sandhiya, Selvarajan
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (04) : 903 - 910
  • [7] A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions
    Belhekar, Mahesh N.
    Taur, Santosh R.
    Munshi, Renuka P.
    [J]. INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 (01) : 117 - 120
  • [8] Sample-size calculations for Cohen's kappa
    Cantor, AB
    [J]. PSYCHOLOGICAL METHODS, 1996, 1 (02) : 150 - 153
  • [9] Goyal R, 2019, INT RES J PHARM, V10, P195
  • [10] 송명균, 2008, [The Korean Journal of Medicine, 대한내과학회지], V74, P181